Please login to the form below

edoxaban

This page shows the latest edoxaban news and features for those working in and with pharma, biotech and healthcare.

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Xarelto no better than aspirin in secondary stroke study

Savaysa (edoxaban) some way behind in third and fourth place, respectively.
Xarelto beats aspirin for recurrent blood clots

edoxaban). Xarelto has slipped from a 60%-plus market share, however, with Eliquis gaining ground in part because of a debate about Xarelto's role in stroke prevention and the design
Portola rejection hands advantage to Boehringer's Pradaxa

Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.
Boehringer starts to feel impact of Spiriva generics

Squibb's Eliquis (apixaban) and Daiichi Sankyo's recently-approved Savaysa (edoxaban).
BMS claims 80% market share for Opdivo in US

and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery. ... Daiichi Sankyo is conducting a large, worldwide, phase III trial of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Add my company

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...